Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + docetaxel + irinotecan
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves **celecoxib**, a selective cyclooxygenase-2 (COX-2) inhibitor; **docetaxel**, a taxane chemotherapy drug; and **irinotecan**, a topoisomerase I inhibitor. The combination was studied for treating advanced solid tumors but was not recommended due to its side effect profile and lack of enhanced efficacy[1][3].
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MicrotubuleTOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on celecoxib + docetaxel + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + docetaxel + irinotecan.